China Biopsy Devices Market to Surpass US$ 1.13 Billion by 2033 Amid Rising Cancer Cases and Technological Advancements

China's Biopsy Devices Market Experiences Strong Growth Driven by Healthcare Innovation and Cancer Burden

According to the latest research report by Renub Research, the China Biopsy Devices Market is poised for substantial growth, reaching a projected value of US$ 1,131.98 million by 2033, up from US$ 612.62 million in 2024, at a CAGR of 7.06% during the forecast period 2025–2033. This expansion is largely attributed to the increasing prevalence of cancer, growing demand for minimally invasive diagnostic techniques, and government-driven improvements in the country’s healthcare infrastructure.

Biopsy devices are critical for the accurate diagnosis of cancer, infectious diseases, autoimmune disorders, and other chronic conditions. As the Chinese population ages and cancer incidence climbs, the healthcare system is under pressure to adopt cutting-edge diagnostic technologies that offer higher precision, faster results, and greater patient comfort.

Key Drivers Powering the Biopsy Devices Market in China

1. Rising Cancer Prevalence in China

Cancer has become the leading cause of death in China, with millions of new cases reported each year. Lung, stomach, liver, colorectal, and breast cancers are among the most common. Biopsy remains the gold standard for confirming cancer, and this rising incidence is directly fueling the demand for advanced biopsy tools.

2. Preference for Minimally Invasive Procedures

Patients and healthcare providers are increasingly opting for minimally invasive diagnostic techniques due to reduced recovery times, fewer complications, and lower healthcare costs. This shift is accelerating the adoption of needle-based and image-guided biopsy systems in hospitals and diagnostic centers.

3. Technological Advancements in Biopsy Devices

Continuous innovation is bringing robot-assisted biopsy systems, vacuum-assisted biopsy (VAB), and 3D image-guided techniques to the forefront of diagnostic medicine in China. These devices provide better tissue sampling accuracy, reduced pain, and improved real-time visualization—transforming the diagnostic workflow.

4. Government Healthcare Reforms and Investments

China’s healthcare reforms aim to improve accessibility and quality of care. Increased public and private investments in diagnostic imaging infrastructure, combined with expanding insurance coverage, are creating a conducive environment for the biopsy devices market to flourish.

Segmentation Overview: A Look Into the China Biopsy Devices Market

By Product Type:

Needle-Based Biopsy Guns
These are widely used for soft tissue biopsies, including breast, prostate, and lung biopsies. The market for core needle biopsy (CNB) and fine needle aspiration biopsy (FNAB) is growing due to their precision and reliability.
Biopsy Needles
Disposable biopsy needles are preferred for reducing the risk of infection. Technological upgrades have enhanced their design for better tissue retrieval and patient safety.
Vacuum-Assisted Biopsy Devices (VAB)
VAB systems are gaining ground in breast cancer diagnostics, as they allow for more tissue extraction with minimal invasiveness, reducing the need for multiple insertions.
Localization Wires and Guidance Systems
These tools are essential in image-guided procedures, offering precise lesion targeting and better biopsy accuracy.
Others (Brush Biopsy, Punch Biopsy, Forceps Biopsy)
Used in dermatology, gastroenterology, and gynecology, these tools cater to specialized applications and are seeing rising demand with the expansion of outpatient services.

By Application:

Breast Cancer
Breast biopsy procedures are increasing due to rising awareness, improved screening, and access to advanced diagnostic centers.
Lung Cancer
Given the high smoking rates and environmental pollution, lung cancer biopsies remain a major diagnostic category, particularly with CT-guided biopsy technologies.
Prostate and Liver Cancer
Advancements in transrectal and transperineal biopsy methods are improving early diagnosis, while liver cancer biopsies benefit from ultrasound and MRI guidance.
Other Applications
These include thyroid, skin, and gastrointestinal biopsies that are becoming more frequent due to increased screening programs and diagnostic awareness.

Regional Insights: Urban Centers Driving Technology Adoption

China's Tier 1 cities like Beijing, Shanghai, Guangzhou, and Shenzhen are at the forefront of biopsy device adoption due to superior healthcare infrastructure and better-trained medical professionals. However, Tier 2 and Tier 3 cities are witnessing rising demand, especially as government initiatives push for healthcare equality and rural diagnostic access.

Telemedicine platforms, AI-driven diagnostics, and mobile diagnostic units are also helping bridge the urban-rural gap, further fueling biopsy procedure uptake across the country.

Competitive Landscape: Key Players & Strategic Developments

China’s biopsy devices market is highly competitive, with both global giants and local innovators vying for market share. Leading companies include:

BD (Becton, Dickinson and Company)
Argon Medical Devices
Cardinal Health
Hologic Inc.
Cook Medical
Devicor Medical Products (part of Leica Biosystems)
Gallini Medical Devices
Planmed Oy
Scion Medical Technologies

Strategic Trends:

Product launches with AI-enhanced imaging and robotic assistance
Joint ventures with local medical device firms
Expansion of after-sales service networks and training centers to improve device adoption in smaller cities
Localization of manufacturing to meet regulatory requirements and cost sensitivity

Market Challenges

Despite the positive outlook, the China biopsy devices market faces several challenges:

Limited access to advanced biopsy technologies in rural regions
Shortage of skilled personnel trained in operating high-end devices
Complex regulatory landscape for new medical technologies
Patient apprehension regarding invasive procedures

To overcome these hurdles, manufacturers are investing in training programs, collaborating with local healthcare providers, and leveraging digital platforms to raise awareness.

Market Outlook: A Future Powered by Precision Diagnostics

As China continues to modernize its healthcare system, diagnostic precision and early detection will be pivotal. Biopsy devices—especially those integrated with imaging, robotics, and AI—will be central to improving oncological outcomes, reducing treatment costs, and enhancing patient satisfaction.

By 2033, China’s biopsy devices market will reflect a fusion of technological sophistication, robust public health strategies, and patient-centric innovations. Stakeholders who invest in localization, R&D, and clinician training today will lead the charge in transforming diagnostic care across the country.

New Publish Report:

About the Company

Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions. We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture. Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.

Media Contact

Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com
Explore Report: https://www.renub.com